Grand Pharmaceutical Group Limited (00512.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.1x

Market Cap

HKD 17.21B

MomentumView details →

1D Return

+0.61%

YTD Return

−37.45%

RSI (14)

38.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.1x

Market Cap

HKD 17.21B

RSI (14)

38.1

MomentumView details →

1D Return

+0.61%

YTD Return

−37.45%

ProfitabilityView details →

Gross Margin

54.78%

Net Margin

13.24%

EBITDA Margin

21.08%

ROE (TTM)

18.61%

ROA (TTM)

11.43%

Asset Turnover

0.88x

GrowthView details →

Revenue YoY

+15.98%

EPS YoY

−33.05%

FCF YoY

+22.73%

Revenue CAGR 3Y

+8.71%

EPS CAGR 3Y

−15.98%

EBITDA YoY

−26.99%

EarningsView details →

EPS (Actual)

HKD 0.28

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.29x

Current Ratio

1.34x

Quick Ratio

1.10x

Div Yield

3.44%

Div Rate

HKD 0.17

Div Growth 1Y

−35.00%

Financials snapshotView financials →

Revenue (TTM)

24.27B

Net Income (TTM)

3.21B

Op. CF (TTM)

3.08B

Next earningsMar 17, 2027 →

Latest newsMore news →

Grand Pharmaceutical's traditional Chinese medicine innovative drug GPN01360 completed first patient dosing in a Phase III clinical study in China for depression.43d ago

Similar companies

健康元600380.SH 华润双鹤600062.SH Livzon Pharmaceutical Group Inc.01513.HK 步长制药603858.SH Neurocrine Biosciences, Inc.NBIX Fujian Haixi Pharmaceuticals Co., Ltd.02637.HK Find similar companies →

Latest newsMore news →

Grand Pharmaceutical's traditional Chinese medicine innovative drug GPN01360 completed first patient dosing in a Phase III clinical study in China for depression.43d ago